微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 17.5% | -22.39% | -11.37% | 138/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 19.75% | -15.43% | -10.11% | 137/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 21.97% | -14.52% | 0.95% | 131/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 21.76% | -15.35% | -3.5% | 135/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 22.55% | -14.21% | -3.42% | 135/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 23.35% | -13.81% | -9.14% | 135/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 25.7% | -8.76% | -0.03% | 127/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 25.71% | -8.93% | -2.2% | 129/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 26.29% | -5.23% | -2.97% | 127/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 27.09% | -2.9% | -3.82% | 127/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 28.17% | 3.28% | -0.21% | 121/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 28.23% | -5.11% | 1.77% | 124/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 27.74% | -10.04% | -0.59% | 122/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 27.9% | -12.07% | 2.3% | 126/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 27.28% | -15.54% | -8.31% | 119/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 29.75% | -14.18% | -3.52% | 128/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 30.83% | -12.25% | -2.84% | 112/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 31.73% | -11.09% | -1.73% | 118/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 32.29% | -11.36% | -6.83% | 101/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 34.66% | -9.15% | -1.35% | 118/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 35.14% | -4.37% | -1.56% | 99/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 35.69% | -0.53% | -2.03% | 107/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 36.43% | -0.69% | -4.51% | 87/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 38.16% | -2.04% | 3.84% | 103/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 36.75% | -1.31% | 2.4% | 83/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 35.88% | 2.26% | -2.19% | 88/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 36.68% | 14.48% | -5.82% | 80/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 38.95% | 27.29% | 4.61% | 98/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 37.24% | 36.75% | 6.11% | 79/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 35.09% | 28.72% | 9.51% | 83/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 32.04% | 20.38% | 4.72% | 82/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 30.6% | 14.98% | 12.38% | 99/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 27.23% | 1.3% | -0.12% | 83/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 27.26% | 0.01% | 2.41% | 86/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 26.62% | 2.28% | 0.03% | 72/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 26.61% | -1.91% | -0.99% | 96/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 26.88% | 0.32% | -1.39% | 65/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 27.26% | 1.6% | 4.73% | 72/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 26.03% | -3.51% | -4.06% | 65/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 27.13% | 2.38% | 1.26% | 85/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 26.79% | 7.2% | -0.13% | 60/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 26.83% | 9.91% | -0.53% | 63/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 26.97% | 11.39% | 1.78% | 57/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |